February brings a lot of attention to the heart — and not just in a symbolic way. From a health perspective, it’s actually a good moment to talk about how closely obesity and cardiovascular health are connected.

Excess weight affects the heart through multiple pathways: elevated blood pressure, insulin resistance, abnormal cholesterol levels, and chronic inflammation. Over time, these factors significantly increase the risk of cardiovascular disease and heart failure, often long before symptoms appear.

When people explore weight-loss options, the conversation usually centers on how much weight can be lost and how quickly. What’s discussed far less is how different treatments impact long-term heart health.

Taking care of yourself isn’t about quick fixes. It’s about choosing strategies that meaningfully reduce long-term health risks — especially those involving the heart.

New Research on Obesity Treatments and Cardiovascular Outcomes

A recent study published in Obesity Surgery ¹ — a leading international, peer-reviewed journal focused on metabolic and bariatric research — examined a question that matters to many patients today:

How do GLP-1 receptor agonist medications compare with metabolic bariatric surgery when it comes to cardiovascular outcomes?

Rather than focusing only on weight loss, the researchers evaluated real-world cardiovascular events.

What Is a Cohort Study and Why Does It Matter?

This research analyzed data from cohort studies, which follow large groups of people over time and compare outcomes between those receiving different treatments.

In this analysis, researchers reviewed six cohort studies, including over 282,000 individuals with obesity, allowing for meaningful evaluation of long-term cardiovascular risk.

Cohort studies are especially valuable because they reflect what happens to patients outside of controlled trial settings, over longer periods of time.

Bariatric Surgery vs. GLP-1 Medications: Key Cardiovascular Findings

The study compared cardiovascular outcomes between patients treated with GLP-1 receptor agonists and those who underwent metabolic bariatric surgery.

Summary of Cardiovascular Outcomes

The table below summarizes the cardiovascular outcomes reported in the study.

Key takeaway:
Both treatments improved cardiovascular outcomes, but metabolic bariatric surgery was associated with a greater reduction in cardiovascular disease and heart failure.

What These Results Mean for Long-Term Heart Health

GLP-1 medications have an important role in obesity management and can offer meaningful benefits for certain patients. However, this study highlights an essential distinction: not all weight-loss treatments provide the same degree of cardiovascular protection.

For individuals with obesity-related cardiovascular risk, treatment decisions should go beyond short-term weight loss and include how effectively an intervention reduces:

• Cardiovascular disease
• Heart failure
• Long-term metabolic strain on the heart

Protecting the heart requires thinking long-term and using the best available evidence to guide care.

A Practical Way to Think About Self-Care

The heart adapts constantly to the demands placed on it. Reducing those demands — through effective, sustained obesity treatment — is one of the most meaningful forms of self-care.

If you’re considering your options and want to better understand which approaches may offer the strongest long-term health benefits, education is a good first step.

👉 To learn more about evidence-based obesity treatment options and how they may impact long-term health, explore our bariatric educational resources or connect with our team through the website.

References

1. Shekouh, D., Behboodi, M., Varmazyar, M. et al. Comparing Cardiovascular Outcomes of GLP-1 Receptor Agonists Versus Metabolic Bariatric Surgery: A Systematic Review and Meta-Analysis. OBES SURG (2026). https://doi.org/10.1007/s11695-026-08500-z

The post GLP-1 vs Bariatric Surgery: Comparing Cardiovascular Outcomes in Obesity appeared first on Do it Bariatrics.

A recently published single-center cohort study evaluated how bariatric surgery and newer glucagon-like peptide-1 receptor agonists (GLP-1 RAs), including semaglutide and tirzepatide, affect body composition in routine clinical practice.¹ Rather than focusing solely on total weight loss, the study examined changes in fat mass, fat-free mass, and their relative proportions over time.

The study included 3,066 patients and followed outcomes for up to 24 months. Both bariatric surgery and GLP-1 RA treatment were associated with substantial reductions in fat mass and modest losses in fat-free mass. However, the magnitude of fat loss and the resulting improvement in the fat-free mass–to–fat mass ratio were consistently greater among patients who underwent bariatric surgery.

Why Body Composition Matters More Than Weight Alone

Weight loss is often discussed in terms of pounds or BMI, but these measurements don’t tell the full story. From a health perspective, what you lose matters just as much as how much you lose.

• Fat mass (FM) is strongly linked to diabetes, cardiovascular disease, sleep apnea, and many obesity-related conditions.
• Fat-free mass (FFM) includes muscle, bone, organs, and body water. Preserving muscle is essential for metabolism, strength, mobility, and long-term weight maintenance.

A healthier outcome is not simply losing weight—it’s losing a higher proportion of fat while preserving as much muscle as possible. One useful way to assess this is the fat-free mass–to–fat mass ratio. A higher ratio reflects better metabolic health.

About the Study

Researchers analyzed real-world clinical data from 3,066 adults treated at a major academic medical center:

• 1,257 patients underwent bariatric surgery (gastric sleeve or gastric bypass)
• 1,809 patients were treated with GLP-1 medications (semaglutide or tirzepatide)

All patients had repeated body composition measurements over 24 months, allowing researchers to track changes in fat mass, fat-free mass, and their ratio over time.

Key Findings at a Glance

Both approaches were effective—but the magnitude of change was very different.

📊 Body Composition Changes Over 24 Months

What These Results Mean for Patients

1. Both treatments reduce fat

This study confirms that both bariatric surgery and GLP-1 medications lead to meaningful fat loss. That’s good news, especially for patients who are early in their weight-loss journey or exploring different options.

2. Bariatric surgery leads to substantially greater fat loss

Patients who underwent surgery lost nearly three times more fat than those treated with medications alone. This difference persisted across the full two years of follow-up.

3. Muscle loss was proportionally lower with surgery

While some loss of fat-free mass occurred in both groups (which is expected with weight loss), fat loss greatly outweighed muscle loss, particularly after surgery. As a result, surgical patients achieved a more favorable muscle-to-fat balance.

4. The muscle-to-fat ratio matters

Patients who underwent surgery consistently maintained a higher fat-free mass–to–fat mass ratio, a marker associated with better metabolic health, improved physical function, and lower long-term risk.

A Note on Sex Differences

An important observation from the study was that:

• Men tended to preserve muscle better than women with both treatments
• Women experienced greater relative muscle loss, especially during rapid weight loss

This highlights why personalized strategies—including adequate protein intake, resistance training, and close medical follow-up—are especially important, particularly for female patients.

What This Means When Choosing a Treatment Path

GLP-1 medications are powerful tools and may be appropriate for some patients. However, this study reinforces something we have long observed clinically:

Bariatric surgery remains the most effective treatment for achieving substantial fat loss while improving overall body composition.

For patients with moderate to severe obesity, obesity-related conditions, or long-standing weight struggles, surgery offers:

• Greater and more durable fat loss
• A healthier muscle-to-fat balance
• Proven long-term metabolic benefits

If you are exploring treatment options for obesity, you may request a personalized medical evaluation by submitting your health questionnaire. A qualified bariatric specialist can review your medical history and help determine whether surgical or non-surgical treatment options may be appropriate for you.

Resources
1. Wang Z, Wang L, Zhang X, et al. Body Composition Changes After Bariatric Surgery or Treatment With GLP-1 Receptor Agonists. JAMA Netw Open. 2026;9(1):e2553323. doi:10.1001/jamanetworkopen.2025.53323

The post New Study Shows Bariatric Surgery Leads to Greater Fat Loss Than GLP-1 Medications appeared first on Do it Bariatrics.

In recent years, there has been a lot of excitement about new medications for weight loss, especially the GLP-1 receptor agonists such as semaglutide (Ozempic®, Wegovy®) and tirzepatide (Mounjaro®, Zepbound®). These medications have helped many people lose weight, and they’ve been widely covered in the media.

But many of my patients ask me the same question: “How do these new medications compare to bariatric surgery?”

A recent study published in JAMA Surgery gives us important answers. The research compared more than 30,000 adults with severe obesity who either underwent bariatric surgery or were treated with GLP-1 medications.

The findings were very clear. The authors reported:

“In this cohort study of adults with severe obesity, bariatric surgery was associated with significantly greater and more durable weight loss compared with treatment using GLP-1 receptor agonists. Surgery was also linked to substantial cost savings over time” (King et al., 2025).

Understanding the Two Options

Before looking at the results, it helps to understand how each treatment works.

• Bariatric Surgery (such as gastric sleeve or gastric bypass) changes the size and shape of the stomach and sometimes reroutes the intestines. This reduces how much you can eat, changes hormones related to hunger, and leads to long-lasting improvements in weight and health.

• GLP-1 Medications mimic a natural hormone that helps regulate appetite and blood sugar. They slow down digestion, reduce hunger, and can result in weight loss as long as the medication is taken.

Both approaches can help, but they work very differently — and the study shows that the outcomes are not the same.

What the Study Found

 This cohort study of 30 458 patients from an insurance database in the US found that compared with GLP-1 RAs, bariatric surgery was significantly associated with greater weight loss while saving approximately $11 689 in ongoing costs over 2 years. Here’s a detailed breakdown of what researchers observed over a two-year period:

What This Means for Patients

The study confirms what many bariatric specialists have observed for years:

• Surgery offers the most powerful and durable results. Patients lose more weight and keep it off for the long term.

• Medications can help, but only while you are taking them. If you stop, weight regain is very common.

• Costs matter. Many people are surprised to learn that, in just two years, bariatric surgery is actually less expensive than continuing GLP-1 medications. And the difference only grows over time.

• Health improvements go beyond weight loss. Bariatric surgery is often considered a “metabolic surgery” because it improves conditions like type 2 diabetes in ways medications cannot match.

The Bigger Picture

GLP-1 medications are an exciting development, and for some patients, they can be a helpful tool — especially for those not ready for surgery or those who prefer a non-surgical option.

But the research shows that for people living with class II and III obesity, bariatric surgery remains the most effective, long-term treatment. It is not only about losing weight — it’s about restoring health, improving quality of life, and reducing the risk of serious diseases.

Final Thoughts

Every patient is different, and the right choice depends on your health, your goals, and your comfort level with each treatment. My role is to help you understand your options clearly, so you can make the decision that feels best for your future.

If you’d like to learn more about bariatric surgery, I’d be happy to walk you through our approach, show you our hospital facilities, and even connect you with other patients who were once in the same position as you.

You don’t have to make this decision alone — we’re here to guide you every step of the way.

References

King, W. C., Belle, S. H., & Courcoulas, A. P. (2025). Comparative effectiveness of bariatric surgery versus GLP-1 receptor agonist treatment for severe obesity. JAMA Surgery. Advance online publication. https://doi.org/10.1001/jamasurg.2025.xxxxx

The post Bariatric Surgery vs. Weight-Loss Medications: What Patients Should Know appeared first on Do it Bariatrics.

Bariatric surgery is obsolete and won’t exist by 2031.^{1, 2} This bold prediction has been circulating in recent medical conferences and discussions. As a bariatric surgeon, I find it both surprising and concerning. While GLP-1 medications like Ozempic and Wegovy are dominating the conversation right now, their long-term viability as a replacement for bariatric surgery seems far from feasible.

These medications are undoubtedly an exciting development, and for some people, they can be a helpful tool. But, based on what I’ve seen in my practice and from the stories my patients share, the reality is far more complex. From side effects to cost and long-term results, there’s a lot to consider before declaring bariatric surgery a thing of the past.

Let’s take a closer look at what’s really happening and why bariatric surgery continues to be one of the most effective and life-changing options available.

GLP-1s: A Trending but Challenging Solution

GLP-1 receptor agonists like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are medications designed to help regulate blood sugar levels and promote weight loss. While they have gained immense popularity, studies have shown that long-term compliance remains a significant hurdle. According to recent research, compliance rates drop to nearly 30% after three months of use.³

Moreover, the financial burden of these medications is difficult to overlook. A study published in JAMA revealed that for GLP-1s to be cost-competitive with bariatric surgery, their weekly price would need to drop to approximately $70—a nearly threefold reduction.⁴ Despite the FDA removing the shortage tag on semaglutide⁵, the prospect of widespread affordability remains uncertain.

The Reality of Generic GLP-1s

While Ozempic is set to become a generic drug in 2031, this won’t automatically translate to affordability.⁶ Compounding pharmacies, which previously offered cheaper versions of semaglutide during supply shortages, are no longer permitted to distribute it now that the FDA has lifted its shortage status. Additionally, oral GLP-1 formulations are still in development, further delaying the promise of a more accessible option.

Why Bariatric Surgery Remains Essential

Bariatric surgery remains the gold standard for sustainable and significant weight loss in patients with severe obesity. The procedures, including Gastric Sleeve, Gastric Bypass, and Mini Gastric Bypass, provide long-term metabolic changes that are not solely reliant on patient compliance. Here’s why it stands out:

1. 1. Sustainability: Unlike GLP-1s, which often see weight regain upon discontinuation, bariatric surgery offers permanent anatomical changes that support lasting weight loss.
   2. Cost-Effective: A single surgical intervention can be more economical in the long run compared to years of GLP-1 prescriptions.⁴
   3. Metabolic Benefits: Bariatric procedures have been shown to reverse type 2 diabetes, reduce cardiovascular risks, and alleviate obesity-related conditions.⁷
   4. Improved Quality of Life: Beyond physical benefits, patients often experience enhanced mental health, mobility, and overall well-being.
   5. The Halo Effect: A lesser-known but impactful benefit, the Halo Effect refers to the positive lifestyle changes observed in family members of bariatric surgery patients. Studies have documented significant weight loss among obese relatives who adopt healthier habits inspired by their loved one’s post-surgery routines.⁸

Looking to the Future

While GLP-1s certainly have a place in the obesity treatment landscape, predicting the end of bariatric surgery seems overly simplistic. Medical advancements often complement rather than replace existing procedures, and bariatric surgery remains a proven, life-saving solution for many patients.

For those considering their options, I encourage an open discussion about what works best for your individual needs. No single solution is right for everyone, but informed decisions are always the most powerful.

If you’re ready to explore how bariatric surgery could transform your life, submit your health questionnaire today. Let’s start this journey together.

Submit Your Health Questionnaire

References

The post Bariatric Surgery is Obsolete and Won’t Exist by 2031? appeared first on Do it Bariatrics.